SNO 2026 has ended. This guide stays up as the record of who was there. See upcoming conferences
Diagnostics, device and service companies at SNO 2026
Nov 12–15, 2026 Philadelphia, PA ~3k attendees Website
14 diagnostics, device and service companies are at SNO 2026 — 21 presentations on the program. Most represented: Novocure (3 on the program), BrainSpec (2 on the program), Oxford University Press (2 on the program). 3 of them have their own page in this guide. As of Nov 12, 2026.
Topic
Top represented
Showing 1–14 of 14 organizations
| Organization | SNO 2026 Attendance |
|---|---|
Novocure St. Helier, Jersey | ◆Platinum Supporter |
A medical technology company that develops tumor treating fields, a therapy used for glioblastoma and other cancers. | Poster Fri Nov 13 7:30–9:30pm Poster Fri Nov 13 7:30–9:30pm Poster Fri Nov 13 7:30–9:30pm |
BrainSpec Boston, MA | ◇Contributing Supporter |
A medical software company that develops magnetic resonance spectroscopy tools for brain tumor assessment. | Talk Fri Nov 13 6–7:15pm Poster Fri Nov 13 7:30–9:30pm |
Oxford University Press Oxford, UK | |
A university press publishing academic books and journals, including scientific and medical research. | Talk Thu Nov 12 11:50am–12:35pm Talk Thu Nov 12 11:50am–12:35pm Talk Thu Nov 12 11:50am–12:35pm |
Medscape New York, NY | |
A medical education and information publisher offering continuing education for healthcare professionals, including oncology education. | Poster Fri Nov 13 7:30–9:30pm |
Ancora.ai Brugg, Switzerland | |
A digital health company providing an AI-powered platform for finding and matching patients to clinical trials. | |
Bracewell Houston, TX | |
A law firm whose attorneys contribute to public policy discussions, including health and biomedical research policy. | Session Thu Nov 12 4:30–5:35pm |
Clario Philadelphia, PA | |
A clinical technology company providing digital data capture and endpoint solutions for clinical trials, including medical imaging. | |
Ember Boston, MA | |
An online AI companion for people and families facing serious illnesses, including glioblastoma, offering information and care-navigation support. | |
MedaSystems Menlo Park, CA | |
A software company providing platforms for expanded-access programs, investigational medicines, and real-world data capture. | |
MERIT CRO Madison, WI | |
A clinical endpoint services provider supporting clinical trials through imaging, endpoint assessment, and related research services. | |
OpenEvidence Cambridge, MA | |
An artificial intelligence platform that provides evidence-based medical information for clinicians. | Talk Sat Nov 14 12:45–2:15pm |
Protean BioDiagnostics Orlando, FL | |
A cancer diagnostics company offering molecular testing, pathology review, and precision oncology services. | |
Belay Diagnostics Charleston, SC | ◇Supporter |
A diagnostics company providing molecular testing and analysis for brain tumors. | Talk Sat Nov 14 7–8:15am |
Oxford Nanopore Technologies Oxford, UK | ◇Contributing Supporter |
A biotechnology company developing nanopore-based DNA and RNA sequencing technology used in molecular diagnostics and research. |
Find buyers from diagnostics, device and service companies
Tell us what you sell and we’ll find the people at these diagnostics, device and service companies most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Browse SNO 2026 by
Organization type
Topic
- Tumor biology: signaling, metabolism, stem cells and the tumor microenvironment 106
- Cancer neuroscience: how neurons and brain tumors interact 54
- Immunobiology, immunotherapy and cell therapies 64
- Experimental therapeutics, drug discovery and resistance, drug delivery and tumor models 105
- Clinical trials, trial design and trials in progress 99
- Molecular pathology, tumor classification and (epi)genomics 102
- Biomarkers and liquid biopsy 53
- Neuroimaging, PET and response assessment 62
- Neurosurgery and surgical therapies 41
- Radiotherapy, radiobiology and radiopharmaceuticals 49
- Pediatric and adolescent and young adult (AYA) brain tumors 55
- Brain and leptomeningeal metastases 27
- Rare CNS tumors and tumor predisposition syndromes 34
- CNS lymphoma and neurohematology 13
- Survivorship, quality of life, cognition, neurologic complications and palliative care 105
- Health disparities, epidemiology and quality improvement 58
Everyone
Not affiliated with or endorsed by the Society for Neuro-Oncology. Submit a correction